A continuing challenge in cancer therapy is effectively killing cancer cells while protecting healthy tissue. Overcoming this obstacle requires the ability to identify and target cancer-related pathways without disturbing normal cell function. Exelixis was founded in 1994 with an initial focus on turning deep biologic insights into novel cancer therapies that have the potential to improve patient outcomes.
This focus has allowed us to establish a successful commercial franchise around our lead…
